Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra

被引:0
|
作者
Tom N Grammatopoulos
Susan M Jones
Ferogh A Ahmadi
Brian R Hoover
Lawrence D Snell
Jesse Skoch
Vimal V Jhaveri
Andy M Poczobutt
James A Weyhenmeyer
W Michael Zawada
机构
[1] Denver and Health Sciences Center,Division of Clinical Pharmacology and Toxicology, Department of Medicine
[2] Denver and Health Sciences Center,Neuroscience Program, Department of Medicine
[3] University of Colorado at Denver and Health Sciences Center,Department of Pharmacology
[4] University of Illinois,Department of Cell and Structural Biology
来源
Molecular Neurodegeneration | / 2卷
关键词
Tyrosine Hydroxylase; Losartan; Ventral Tegmental Area; Angiotensin Converting Enzyme Inhibitor; MPTP Injection;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 30 条
  • [1] Quantification of MPTP-induced dopaminergic neurodegeneration in the mouse substantia nigra by laser capture microdissection
    Stephenson, Diane
    Ramirez, Andres
    Long, Jill
    Barrezueta, Nestor
    Hajos-Korcsok, Eva
    Matherne, Curt
    Gallagher, Dan
    Ryan, Anne
    Ochoa, Ricardo
    Menniti, Frank
    Yan, James
    JOURNAL OF NEUROSCIENCE METHODS, 2007, 159 (02) : 291 - 299
  • [2] Protein tyrosine phosphatase inhibition reduces degeneration of dopaminergic substantia nigra neurons and projections in 6-OHDA treated adult rats
    Yang, Peng
    Dankowski, Aygul
    Hagg, Theo
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2007, 25 (05) : 1332 - 1340
  • [3] Running exercise protects the substantia nigra dopaminergic neurons against inflammation-induced degeneration via the activation of BDNF signaling pathway
    Wu, Shih-Ying
    Wang, Tzu-Feng
    Yu, Lung
    Jen, Chauying J.
    Chuang, Jih-Ing
    Wu, Fong-Sen
    Wu, Chih-Wei
    Kuo, Yu-Min
    BRAIN BEHAVIOR AND IMMUNITY, 2011, 25 (01) : 135 - 146
  • [4] Immunohistochemical evidence for localization of NMDAR1 receptor subunit on dopaminergic neurons of the rat substantia nigra, pars compacta
    Wedzony, K
    Czepiel, K
    Fijal, K
    POLISH JOURNAL OF PHARMACOLOGY, 2001, 53 (06): : 675 - 679
  • [5] CaV1.3 L-Type Calcium Channels Increase the Vulnerability of Substantia Nigra Dopaminergic Neurons in MPTP Mouse Model of Parkinson's Disease
    Verma, Aditi
    Ravindranath, Vijayalakshmi
    FRONTIERS IN AGING NEUROSCIENCE, 2020, 11
  • [6] The angiotensin II type I receptor antagonist losartan retards amygdala kindling-induced epileptogenesis
    Nozaki, Toshiki
    Ura, Hiroyuki
    Takumi, Ichiro
    Kobayashi, Shiro
    Maru, Eiichi
    Morita, Akio
    BRAIN RESEARCH, 2018, 1694 : 121 - 128
  • [7] Vasomodulatory effects of the angiotensin II type 1 receptor antagonist losartan on experimentally induced cerebral vasospasm after subarachnoid haemorrhage
    Wanderer, Stefan
    Mrosek, Jan
    Gessler, Florian
    Seifert, Volker
    Konczalla, Juergen
    ACTA NEUROCHIRURGICA, 2018, 160 (02) : 277 - 284
  • [8] Therapeutic Effect of Losartan, an Angiotensin II Type 1 Receptor Antagonist, on CCl4-Induced Skeletal Muscle Injury
    Hwang, Ok-Kyung
    Park, Jin-Kyu
    Lee, Eun-Joo
    Lee, Eun-Mi
    Kim, Ah-Young
    Jeong, Kyu-Shik
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (02)
  • [9] The angiotensin II type 1 receptor antagonist Losartan binds and activates bradykinin B2 receptor signaling
    Bonde, Marie Mi
    Olsen, Kristine Boisen
    Erikstrup, Niels
    Speerschneider, Tobias
    Lyngso, Christina
    Haunso, Stig
    Nielsen, Morten Schak
    Sheikh, Soren P.
    Hansen, Jakob Lerche
    REGULATORY PEPTIDES, 2011, 167 (01) : 21 - 25
  • [10] Protective effects of the angiotensin type 1 receptor antagonist losartan in infection-induced and arthritis-associated alveolar bone loss
    Queiroz-Junior, C. M.
    Silveira, K. D.
    de Oliveira, C. R.
    Moura, A. P.
    Madeira, M. F. M.
    Soriani, F. M.
    Ferreira, A. J.
    Fukada, S. Y.
    Teixeira, M. M.
    Souza, D. G.
    da Silva, T. A.
    JOURNAL OF PERIODONTAL RESEARCH, 2015, 50 (06) : 814 - 823